Cancer Letters

Cancer Letters

Volume 119, Issue 2, 11 November 1997, Pages 227-235
Cancer Letters

Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer

https://doi.org/10.1016/S0304-3835(97)00280-2Get rights and content

Abstract

To examine the association of vascular endothelial growth factor (VEGF) expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor (dThdPase/PD-ECGF) expression in human colorectal cancer, immunohistochemical studies were performed on 136 cases of resected colorectal cancer specimens using antibodies for VEGF, KDR, CD34 and dThdPase/PD-ECGF. Fifty-nine cases (43%) were evaluated as positive for VEGF staining and 71 cases (52%) were evaluated as positive for dThdPase/PD-ECGF staining. The expression of VEGF correlated significantly with vessel counts and the expression of dThdPase/PD-ECGF (P = 0.01 and 0.01, respectively). Cox proportional hazards model analysis showed that vessel counts and VEGF expression were significant and independent prognostic factors, but that KDR expression was not.

References (52)

  • G. Fontanini et al.

    Microvessel count predicts metastatic disease and survival in non-small cell lung cancer

    J. Pathol.

    (1995)
  • N. Tanigawa et al.

    Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas

    Cancer Res.

    (1996)
  • H.F. Dvorak et al.

    Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor secreted products

    J. Immunol.

    (1979)
  • H. Ohtani et al.

    Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract

    Lab. Invest.

    (1993)
  • T. Furukawa et al.

    Angiogenic factor

    Nature

    (1992)
  • D.S. Grant et al.

    Scatter factor induces blood vessel formation in vivo

  • L.T. Malden et al.

    Expression of transforming growth factor alpha messenger RNA in the normal and neoplastic gastrointestinal tract

    Int. J. Cancer

    (1989)
  • R.K. Singh et al.

    Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells

    Am. J. Pathol.

    (1994)
  • K.M. Dameron et al.

    Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

    Science

    (1994)
  • J. Folkman

    Angiogenesis: initiation and modulation

  • L.F. Brown et al.

    Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas

    Am. J. Pathol.

    (1993)
  • K.J. Kim et al.

    Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

    Nature

    (1993)
  • R.S. Warren et al.

    Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

    J. Clin. Invest.

    (1995)
  • N. Tanigawa et al.

    Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma

    J. Clin. Oncol.

    (1997)
  • N. Tanigawa et al.

    Tumor angiogenesis and mode of metastasis in patients with colorectal cancer

    Cancer Res.

    (1997)
  • M. Toi et al.

    Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer

    Int. J. Cancer

    (1995)
  • Cited by (94)

    • Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma

      2020, European Journal of Medicinal Chemistry
      Citation Excerpt :

      These VEGFRs reside on the exterior of vascular endothelial cells, lymph vessels, and hematopoietic stem cells [5]. Among three VEGFRs, overexpression of VEGFR-2 is prominent in the various cancers, viz. HCC, RCC, NSCLC, TNBC, breast cancer, bladder cancer, and cervical cancer, thus VEGFR-2 is a recognized target for the discovery of anti-angiogenic agents to prevent tumor progression [6–12]. There are three types of VEGFR-2 inhibitors: ATP competitive inhibitors (type I), allosteric inhibitors (type II), and covalent inhibitors (type III) [13].

    • Review on TAS-102 development and its use for metastatic colorectal cancer

      2016, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      Later, they were identified as having the same protein structure and biological functions (Moghaddam and Bicknell, 1992; Moghaddam et al., 1995). PD-ECGF/TP increases endothelial cell migration and neovascular sprouting (Moghaddam et al., 1995; Hotchkiss et al., 2003) and may provide a VEGF-alternative mechanism for neovascularization, since tumors exhibiting high blood vessel density in conjunction with low VEGF expression often present high levels of PD-ECGF/TP (Amaya et al., 1997). PD-ECGF/TP is commonly overexpressed in colorectal cancer cells (van Triest et al., 2000) and in elements of the tumor microenvironment, such as the tumor-associated macrophages (Takahashi et al., 1996).

    • Is VEGF a predictive biomarker to anti-angiogenic therapy?

      2011, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      These different findings about the correlation of VEGF with prognosis make it difficult to draw definitive conclusions as to the prognostic value of VEGF measurement whether in tumor or in serum. Several studies have found that increased VEGF expression is associated with tumor progression [23,25,33] and VEGF has also been shown to correlate with the extent of tumor vascularization in many studies [24,33,35]. Some studies have evaluated whether VEGF receptor expression correlates with prognosis.

    View all citing articles on Scopus
    View full text